Johnson & Johnson (JNJ)


NYSE - NYSE Real Time Price. Currency in USD
118.13+0.86 (+0.73%)
At close: 4:00 PM EDT
People also watch:
PGMRKKOPFEXOM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open117.78
Prev Close117.27
Bid117.85 x 400
Ask118.29 x 500
Day's Range117.39 - 118.62
52wk Range92.58 - 126.07
1y Target EstN/A
Market Cap323.19B
P/E Ratio (ttm)22.01
Beta0.70
Volume7,150,518
Avg Vol (3m)6,259,060
Dividend & Yield3.20 (2.73%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters9 hours ago

    J&J psoriasis drug tops placebo, Humira in late stage study

    An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. More than 73 percent of patients who received guselkumab experienced near complete skin clearance compared with 2.9 percent those who received a placebo. In the Humira group, nearly 50 percent of patients saw near complete skin clearance.

  • Bloomberg9 hours ago

    J&J’s Skin Drug Beats Humira in Final-Stage Psoriasis Study

    Johnson & Johnson’s experimental drug for psoriasis hit its main goals and outperformed a rival in a final-stage study, positioning the company to expand its arsenal of immune-disease treatments.

  • Reuters10 hours ago

    Novartis psoriasis drug maintains efficacy after 4 years - study

    Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.